USA-based Eleven Biotherapeutics (Nasdaq: EBIO) has announced it has acquired Canadian company Viventia Bio to create a targeted protein therapeutics oncology company.
Under the agreement Eleven will purchase all the outstanding capital stock of Viventia in exchange for 4,013,431 newly issued shares of Eleven stock, valuing the company at around $13.5 million. News of the deal pushed Eleven's share price up as much at 25%.
The company will continue to be named Eleven Biotherapeutics but will be led by Vivientia’s chief executive officer, Stephen Hurly.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze